Esophageal Cancer Drugs Market Size, Shares, Insights, Forecast 2018-2026

1. ESOPHAGEAL CANCER DRUGS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Esophageal Cancer Drugs Market - Overview Global Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramucirumab), and Immunotherapy (Pembrolizumab)), By Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 765.2 million in 2018 and is projected to exhibit a CAGR of 8.2% over the forecast period (2019 - 2027), as highlighted in a new report published by. Disease Indication (Adenocarcinomas, Increasing cancer research, Food and Drug Administration (FDA) approvals-based drug discovery, and rising number of development programs and pipeline drugs among others are the major factors that are expected to drive growth of the esophageal cancer drugs market. Various pharmaceutical companies are focused on research and development of novel drug therapies for the treatment of esophageal cancer drugs. For instance, in November 2018, Merck & Co., Inc. revealed the results of phase 3 clinical trial of Keytruda (pembrolizumab), which indicates Keytruda reduced the risk of death compared to chemotherapy in patients with squamous cell carcinoma or adenocarcinoma. Browse Research Reports: https://www.coherentmarketinsights.com/market- insight/esophageal-cancer-drugs-market-3036 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Manufacturers in the esophageal cancer drugs market are focusing on increasing product portfolio by receiving Food and Drug Administration (FDA) approvals to further boost the esophageal cancer drug market size. In April 2014, FDA approved Cyramza (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma. Browse 38 Market Data Tables and 27 Figures spread through 166 Pages and in-depth TOC on "Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy Immunotherapy (Pembrolizumab)), By Disease Indication (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) (Trastuzumab and Ramucirumab), and Many companies such as Pfizer Inc., Merck & Co., Bristol-Meyer Squibb, and Eli Lilly & Company are focused on drugs that are under development in the pipeline such as Ipilimumab and Nivolumab and are expected to be launched in the near future. For instance, in 2018, Bristol-Meyer Squibb’s Opdivo (Nivolumab) intravenous infusion injection and Yervoy Injection was in the developmental pipeline. It is in phase III for treatment of stomach cancer and is expected to launch in the U.S., Europe, South Korea, and Taiwan in the near future Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/3036 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Key Takeaways of the Esophageal Cancer Drugs Market: The global esophageal cancer drugs market is expected to expand at a CAGR of 8.2% during the forecast period (2019–2027), owing to increasing research & development and demand for genomic and repertoire sequencing-based research Among therapy type, the immunotherapy segment is expected to account for maximum share over the forecast period. For instance, in 2017, pembrolizumab (Keytruda) was approved by the U.S. Food and Drug Administration (FDA) to treat gastroesophageal cancer in some patients whose previous treatment did not work or stopped working, and it was proved to be better than chemotherapy. Major players operating in the global esophageal cancer drugs market include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3036 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved